Phase I trial of MGN 1404, TNF-alpha expressing MIDGE-vector non-viral gene transfer, in patients with malignant melanoma.

Trial Profile

Phase I trial of MGN 1404, TNF-alpha expressing MIDGE-vector non-viral gene transfer, in patients with malignant melanoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2013

At a glance

  • Drugs MGN 1404 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2013 Status changed from not yet recruiting to recruiting, according to a Mologen media release.
    • 15 Apr 2013 Approval has been granted by the Paul-Ehrlich Institute, according to a Mologen media release.
    • 02 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top